The Interleukin Inhibitors Market is expected to register a CAGR of 12.5% during the forecast period. The major factors driving the growth of the market include increasing global prevalence of autoimmune disorders and rising geriatric popuation and technological advancements in the development of novel interleukin inhibitors.
Furthermore, there has been a significant paradigm shift in the treatment of autoimmune diseases. The preference for targeted therapies is increasing due to their improved safety and efficacy profiles which is expected to boost the market growth.
According to the Centers for Disease Control and Prevention (CDC) report, in 2018, around 7.9% of the population of the United States had asthma. Asthma is more common among females and children aged 5 to 14 years. In children, the prevalence rate was 7.5% and in adults 7.7%. Moreover, currently available interleukin based treatment are very effective at controlling asthma in the majority of patients. For instance, GlaxoSmithKline Plc offers Nucala which is a humanized, interleukin-5 (IL-5) antagonist monoclonal antibody used in the treatment of severe eosinophilic asthma. Thus, owing to above mentioned factors it is expected to drive market growth over the forecast period.
Key Market Trends
Psoriasis Segment is Expected to Hold a Significant Market Share Over the Forecast Period.
Psoriasis is one of the most common chronic skin diseases which is likely to increase with age. The major factors driving the psoriasis segment growth include increasing disease prevalence, growing consumer awareness, and favorable reimbursement policies. Some of the effective FDA approved interleukin inhibitors for psoriasis treatment include Stelara, Cosentyx, Siliq and Taltz.
According to the International Federation of Psoriasis Associations 2020, estimates that more than 125 million people around the world have psoriasis. In addition, people living with psoriasis have an increased risk of co-morbidities such as diabetes and cardiovascular disease. The impact on mental health can also be significant. In order to prevent such co-morbidities associated with psoriasis is llikely to increase demand for interleukin inhibitors over the forecast period.
In addition, in 2020, UCB announched that U.S Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for bimekizumab (UCB) for the treatment of moderate to severe plaque psoriasis in adults. Thus, owing to above mentioned factors it is expected to drive market growth in near future.
North America Region is Expected to Hold a Major Market Share Over the Forecast Period
In North America region, the United States is expected to hold signifcant market share due to presence of major market players, increasing research and development activities in the development of novel products, proactive government initiatives and increase in healthcare expenditure..
Factors such presence of key pipeline products and label expansions of existing products indicated for psoriatic arthritis, Crohn’s disease, and ulcerative colitis, are key growth propellers. According to the National Clinical Trial (NCT) Registry, as of December 2020, there are more than 200 ongoing clinical trials related to interleukin inhibitors in the United States across different phases of development for various indications. Thus, owing to above mentioned factors, the market in the United States is expected to be one of the largest and is also expected to grow in the future.
Competitive Landscape
The Interleukin Inhibitors Market is moderately consolidated competitive. Some market players are focusing on implementing strategies such as partnerships, distribution agreements, and regional expansion to increase their revenue share. Some of the market players include Johnson and Johnson, Novartis AG, AbbVie Inc, Eli Lilly and Company, AstraZeneca Plc, Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Teva Pharmaceuticals Industries, Ltd and others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
Methodology
LOADING...
